% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kuhn:278782,
      author       = {Kuhn, Elizabeth and Klinger, Hannah M and Amariglio,
                      Rebecca E and Wagner, Michael and Jessen, Frank and Düzel,
                      Emrah and Heneka, Michael T and Chételat, Gael and Rentz,
                      Dorene M and Sperling, Reisa A and Ebenau, Jarith L and
                      Butterbrod, Elke and Van Der Flier, Wiesje M and Sikkes,
                      Sietske A M and Teunnissen, Charlotte E and Van Harten,
                      Argonde C and Van De Giessen, Elsmarieke M and Rami, Lorena
                      and Tort, Adria and Sánchez Benavides, Gonzalo and Gifford,
                      Katherine A and Van Hulle, Carol and Buckley, Rachel F and
                      Biomarkers, Australian Imaging},
      collaboration = {Initiative, Alzheimer's Disease Neuroimaging and Lifestyle
                      flagship study of ageing, A4 Study Team and Study, DELCODE
                      and Study, Harvard Aging Brain},
      othercontributors = {Brosseron, Frederic and Bürger, Katharina and Laske,
                          Christoph and Perneczky, Robert and Peters, Oliver and
                          Priller, Joseph and Ramirez, Alfredo and Schneider, Anja and
                          Spottke, Annika and Teipel, Stefan and Wiltfang, Jens},
      title        = {{SCD}-plus features and {AD} biomarkers in cognitively
                      unimpaired samples: {A} meta-analytic approach for nine
                      cohort studies.},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {5},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00618},
      pages        = {e14307},
      year         = {2025},
      abstract     = {Specific features of subjective cognitive decline
                      (SCD-plus) have been proposed to indicate an increased risk
                      of preclinical Alzheimer's disease (AD). However, few
                      studies have examined how these features relate to AD
                      biomarkers in cognitively unimpaired (CU) older
                      adults.Meta-analyses were performed using cross-sectional
                      data from nine cohorts (n = 7219, mean age (SD): 71.17
                      (5.9), $56.5\%$ female) to determine associations of
                      SCD-plus features with positron emission tomography (PET)-
                      or cerebrospinal fluid (CSF)-derived amyloid beta (Aβ) and
                      tau biomarkers.Participants with preclinical AD
                      (community-based only) were more likely to fulfill SCD-plus
                      features. The presence of self-reported memory decline,
                      associated concern/worry, and a higher number of fulfilled
                      features were all associated with high Aβ levels. Only the
                      latter was associated with abnormal tau.Simultaneous
                      endorsement of multiple SCD-plus features is a robust
                      indicator of abnormal AD biomarkers in CU older adults,
                      whereas isolated SCD features seem only sensitive to
                      elevated Aβ, supporting their value as early behavioral
                      markers of preclinical AD.About two-tenths of our sample had
                      abnormal amyloid beta (Aβ) levels with evidence of
                      subjective cognitive decline (SCD). Preclinical AD
                      subsamples (community-based) had a higher percentage of
                      participants meeting SCD-plus features. Self-reported memory
                      decline and concern/worry were the sole features associated
                      with high Aβ, but not tau, burden. A higher number of
                      fulfilled SCD-plus features are linked to high Aβ and tau
                      burden. Use of multiple SCD-plus features may help identify
                      early stages of biological AD.},
      keywords     = {Humans / Biomarkers: cerebrospinal fluid / Alzheimer
                      Disease: cerebrospinal fluid / Alzheimer Disease: diagnosis
                      / Alzheimer Disease: diagnostic imaging / Cognitive
                      Dysfunction: cerebrospinal fluid / Cognitive Dysfunction:
                      diagnosis / Amyloid beta-Peptides: cerebrospinal fluid / tau
                      Proteins: cerebrospinal fluid / Positron-Emission Tomography
                      / Female / Male / Aged / Cohort Studies / Cross-Sectional
                      Studies / Alzheimer's disease (Other) / SCD‐Initiative
                      (Other) / amyloid pathology (Other) / cerebrospinal fluid
                      (Other) / meta‐analysis (Other) / positron emission
                      tomography (Other) / subjective cognitive decline (Other) /
                      tau burden (Other) / Biomarkers (NLM Chemicals) / Amyloid
                      beta-Peptides (NLM Chemicals) / tau Proteins (NLM
                      Chemicals)},
      cin          = {AG Wagner / AG Jessen / AG Düzel},
      ddc          = {610},
      cid          = {I:(DE-2719)1011201 / I:(DE-2719)1011102 /
                      I:(DE-2719)5000006},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      experiment   = {EXP:(DE-2719)DELCODE-20140101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39985404},
      pmc          = {pmc:PMC12079645},
      doi          = {10.1002/alz.14307},
      url          = {https://pub.dzne.de/record/278782},
}